OTC Markets OTCPK - Delayed Quote USD

Novartis AG (NVSEF)

99.24

0.00

(0.00%)

At close: January 10 at 3:00:00 PM EST

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks yesterday

BSX

NVS
AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.  In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.

Yahoo Finance Video yesterday

PFE

NVS

NVSEF
0.00%
Light Horse emerges with $62m and Novartis partnership worth up to $1bn

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Pharmaceutical Technology yesterday

NVS
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 2 days ago

NVS
Why Novartis (NVS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 4 days ago

NVS
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Zacks 8 days ago

PFE

SGMO

NVS
Positive data could expand use of Novartis’ gene therapy for SMA

Zolgensma represents the first and only gene transfer therapy for the treatment of SMA.

Clinical Trials Arena 8 days ago

NVS
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.

Zacks 11 days ago

NVS
Here's Why Novartis (NVS) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 11 days ago

NVS
Novartis’ Gene Therapy Shows Promise in Treating SMA

Novartis ( (NVS) ) has provided an update. Novartis announced the success of its Phase III STEER study for investigational intrathecal onasemnogene abeparvovec (OAV101 IT) in treating spinal muscular atrophy (SMA) Type 2 in children and young adults. The study demonstrated an increase in motor function, showcasing the therapy’s efficacy and safety compared to a sham control. Novartis plans to seek regulatory approval in 2025, which could enhance treatment options for SMA patients and strengthen

TipRanks 11 days ago

NVS

NVSEF
0.00%
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint

In the trial, an increase in total Hammersmith Functional Motor Scale – Expanded scores was reported.

Clinical Trials Arena 11 days ago

NVS
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT)OAV101 IT is the first investigational gene therapy to provide clinical benefit in treatment-naïve patients with SMA aged two and older with a positive risk benefit profileNovartis plans to share results with regulatory agencies in 2025 with the aim to make OAV101 IT a

GlobeNewswire 12 days ago

NVS

NVSEF
0.00%
Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other cheap healthcare stocks. The Resilience and Challenges of Global Healthcare Spending Investing in healthcare equities is typically seen as protective during […]

Insider Monkey 13 days ago

NVS
Sector Update: Health Care Stocks Lower in Late Afternoon Trading

Health care stocks were declining late Friday afternoon, with the NYSE Health Care Index down 0.7% a

PREMIUM
MT Newswires 14 days ago

NVS

UNH
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

NEW YORK (Reuters) -A U.S. appeals court on Friday revived a whistleblower lawsuit accusing Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya. In a 3-0 decision, the 2nd U.S. Circuit Court of Appeals in Manhattan said the whistleblower Steven Camburn can try to prove that Novartis violated the federal False Claims Act by holding "sham" speaker events to boost Gilenya sales. Camburn, a former Novartis sales representative, said the drugmaker paid doctors thousands of dollars and treated them to dinners at high-end restaurants to speak at purportedly educational events that were actually social in nature.

Reuters 15 days ago

NVS
Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other European dividend stocks. Dividend payouts for MSCI Europe companies hit a record €407 billion in 2023, and they are set to grow even […]

Insider Monkey 19 days ago

NVS
Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term

These five laggards of this year have double-digit upside left in the near term. They are: UBER, NVS, RYAAY, OKTA, BAH.

Zacks 19 days ago

OKTA

RYAAY

UBER
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 22 days ago

NVS
Novartis shutters MorphoSys sites, lays off staff

While the pharma is still developing a MorphoSys drug acquired in its $2.9 billion deal for the biotech, it is closing down sites in the U.S. and Germany.

BioPharma Dive 23 days ago

NVS
BioAge and Novartis seek drug targets for ageing-related diseases

BioAge will receive an upfront payment and research funding of up to $20m.

Pharmaceutical Technology 23 days ago

BIOA

NVS

Performance Overview

Return	NVSEF	MSCI WORLD
YTD	+3.27%	-1.09%
1-Year	-2.81%	+16.88%
3-Year	+33.67%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novartis AG (NVSEF)

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Light Horse emerges with $62m and Novartis partnership worth up to $1bn

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More

Positive data could expand use of Novartis’ gene therapy for SMA

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study

Here's Why Novartis (NVS) is a Strong Growth Stock

Novartis’ Gene Therapy Shows Promise in Treating SMA

Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025

Sector Update: Health Care Stocks Lower in Late Afternoon Trading

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?

Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Novartis shutters MorphoSys sites, lays off staff

BioAge and Novartis seek drug targets for ageing-related diseases

Performance Overview